News
ZBIO
8.25
-5.50%
-0.48
Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth?
Simply Wall St · 1d ago
Zenas BioPharma Price Target Maintained With a $45.00/Share by Guggenheim
Dow Jones · 2d ago
Guggenheim Reiterates Buy on Zenas BioPharma, Maintains $45 Price Target
Benzinga · 2d ago
Zenas BioPharma Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $30 Price Target
Benzinga · 2d ago
Weekly Report: what happened at ZBIO last week (0303-0307)?
Weekly Report · 4d ago
Adobe, DICK's Sporting Goods, Dollar General To Report Results As Investors Look To Inflation Report
Seeking Alpha · 6d ago
Weekly Report: what happened at ZBIO last week (0224-0228)?
Weekly Report · 03/03 12:51
Top-rated biotechs with negative enterprise values
Seeking Alpha · 03/01 19:28
Weekly Report: what happened at ZBIO last week (0217-0221)?
Weekly Report · 02/24 12:50
Weekly Report: what happened at ZBIO last week (0210-0214)?
Weekly Report · 02/17 12:46
Director Makes Bold Move with Major Stock Purchase in Zenas BioPharma!
TipRanks · 02/12 02:02
Weekly Report: what happened at ZBIO last week (0203-0207)?
Weekly Report · 02/10 12:36
Zenas BioPharma Reports Strong 2024 Momentum, Eyes 2025 Milestones In Obexelimab Trials for Lupus, Multiple Sclerosis, And IgG4-RD
Benzinga · 02/05 12:24
ZENAS BIOPHARMA- CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AS OF DEC 31 TO FUND OPERATING EXPENSES & CAPEX REQUIREMENTS INTO Q4 2026
Reuters · 02/05 12:09
ZENAS BIOPHARMA :TOPLINE RESULTS FROM PIVOTAL PHASE 3 TRIAL IN IMMUNOGLOBULIN G4-RELATED DISEASE (INDIGO) EXPECTED YEAR-END 2025
Reuters · 02/05 12:08
ZENAS BIOPHARMA : TOPLINE RESULTS FROM PHASE 2 TRIAL IN RELAPSING MULTIPLE SCLEROSIS (MOONSTONE) EXPECTED IN Q3 2025
Reuters · 02/05 12:08
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
Barchart · 02/05 06:05
Zenas BioPharma Price Target Announced at $19.00/Share by Wolfe Research
Dow Jones · 02/04 13:26
Wolfe Research Initiates Coverage On Zenas BioPharma with Outperform Rating, Announces Price Target of $19
Benzinga · 02/04 13:16
More
Webull provides a variety of real-time ZBIO stock news. You can receive the latest news about Zenas BioPharma Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ZBIO
More
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on the development and commercialization of immunology-based therapies for patients in need. Its lead immunology and inflammation (I&I) product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. It is developing obexelimab as a potential I&I franchise for patients in several autoimmune diseases. Its pipeline also includes two global programs, ZB002 (an anti-TNFα monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion), and two regional programs, ZB001 (also known as VRDN-001, an IGF-1R monoclonal antibody), and related programs, and ZB005 (also known as DNTH103, an anti-active C1s monoclonal antibody), for which the Company hold the development and commercialization rights in greater China.